Compare ASML Holding NV (ASML) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASML Holding NV vs TG Therapeutics Inc — how do they compare? ASML Holding NV trades at $1,813.56 (market cap $689.17B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: ASML Holding NV is far larger — about 90.2× TG Therapeutics Inc's market cap, and ASML Holding NV pays a 0.5% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ASML | TGTX | |
|---|---|---|
Market Cap | $689.17B | $7.64B |
Sector | Technology | Health |
52-Week High | $1.99K | $59.06 |
52-Week Low | $725.85 | $26.94 |
Enterprise Value | $682.70B | $7.84B |
Dividend Yield | 0.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASML trades at $1,810.93, up 4.47% today, with a bullish technical signal from moving averages and strong analyst consensus. The stock is near its pivot point of $1,799, with resistance at $1,820. Recent earnings beat expectations in Q1 and Q2 2026, and revenue grew to $32.67 billion in 2025. The company maintains high profitability with a net margin of 27.78% and robust cash flow from operations of $12.66 billion.
Outlook remains positive due to AI-driven semiconductor demand, but risks include high valuation multiples and geopolitical tensions affecting Chinese business. Analysts see upside to a $2,390 consensus target, with 57% recommending buy. Institutional interest is strong, though the stock faces overbought signals on short-term RSI.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
